Environmental or self-antigens and homotypic interactions set off BCR and Toll-like receptor (TLR) signaling, amplifying the reaction of CLL cells to other signals from the microenvironment and raising the activation of anti-apoptotic and proliferation pathways.Duvelisib was the 2nd PI3K inhibitor permitted through the FDA, also based on a period I